TIGIT and acute myeloid leukemia: Finally, TIGIT was considered since its blockade in combination with other blocking antibodies resulted in enhanced NK-92 cytotoxicity against AML and its ligands CD112 and CD155 expressed in several target cell lines (Figure 1a,c) [31].